Hansoh Pharmaceutical Group Company Limited

OTCPK:HNSP.F Stock Report

Market Cap: US$13.7b

Hansoh Pharmaceutical Group Valuation

Is HNSP.F undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

4/6

Valuation Score 4/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of HNSP.F when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: HNSP.F ($2.7) is trading below our estimate of fair value ($4.04)

Significantly Below Fair Value: HNSP.F is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for HNSP.F?

Key metric: As HNSP.F is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for HNSP.F. This is calculated by dividing HNSP.F's market cap by their current earnings.
What is HNSP.F's PE Ratio?
PE Ratio21.2x
EarningsCN¥4.71b
Market CapCN¥99.90b

Price to Earnings Ratio vs Peers

How does HNSP.F's PE Ratio compare to its peers?

The above table shows the PE ratio for HNSP.F vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average23x
RPRX Royalty Pharma
9.7x6.3%US$14.3b
JAZZ Jazz Pharmaceuticals
16.1x16.3%US$7.4b
ELAN Elanco Animal Health
28x1.6%US$5.8b
CORT Corcept Therapeutics
38.3x41.4%US$5.4b
HNSP.F Hansoh Pharmaceutical Group
21.2x3.5%US$106.5b

Price-To-Earnings vs Peers: HNSP.F is good value based on its Price-To-Earnings Ratio (21.2x) compared to the peer average (23x).

Price to Earnings Ratio vs Industry

How does HNSP.F's PE Ratio compare vs other companies in the US Pharmaceuticals Industry?

9 CompaniesPrice / EarningsEstimated GrowthMarket Cap
OGN Organon
2.9x-8.3%US$3.72b
NDOI Endo
0.5xn/aUS$1.83b
KPRX Kiora Pharmaceuticals
1.8x-40.4%US$9.72m
EDXC Endexx
0.8xn/aUS$5.25m
HNSP.F 21.2xIndustry Avg. 16.7xNo. of Companies9PE01224364860+
9 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: HNSP.F is expensive based on its Price-To-Earnings Ratio (21.2x) compared to the US Pharmaceuticals industry average (16.9x).

Price to Earnings Ratio vs Fair Ratio

What is HNSP.F's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

HNSP.F PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio21.2x
Fair PE Ration/a

Price-To-Earnings vs Fair Ratio: Insufficient data to calculate HNSP.F's Price-To-Earnings Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst HNSP.F forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentUS$2.70
US$3.00
+11.0%
13.4%US$3.77US$2.25n/a20
Dec ’25n/a
US$2.98
0%
13.1%US$3.79US$2.26n/a21
Nov ’25n/a
US$3.02
0%
12.9%US$3.86US$2.30n/a21
Oct ’25n/a
US$3.00
0%
11.1%US$3.73US$2.34n/a21
Sep ’25n/a
US$2.89
0%
12.3%US$3.67US$2.31n/a21
Aug ’25n/a
US$2.57
0%
13.8%US$3.57US$2.18n/a19
Jul ’25n/a
US$2.49
0%
15.2%US$3.55US$1.91n/a18
Jun ’25n/a
US$2.46
0%
15.7%US$3.57US$1.91n/a18
May ’25n/a
US$2.42
0%
15.8%US$3.57US$1.89n/a19
Apr ’25n/a
US$2.31
0%
16.1%US$3.58US$1.75n/a18
Mar ’25n/a
US$2.13
0%
20.8%US$3.21US$1.43n/a19
Feb ’25US$1.50
US$2.15
+43.5%
20.7%US$3.24US$1.44n/a19
Jan ’25n/a
US$2.11
0%
21.8%US$3.27US$1.45n/a19
Dec ’24n/a
US$2.09
0%
21.8%US$3.25US$1.44n/a19
Nov ’24n/a
US$1.98
0%
23.5%US$3.16US$1.29n/a19
Oct ’24n/a
US$2.00
0%
23.2%US$3.18US$1.29n/a19
Sep ’24n/a
US$2.09
0%
23.3%US$3.53US$1.30n/a19
Aug ’24n/a
US$2.24
0%
18.3%US$3.59US$1.54n/a19
Jul ’24n/a
US$2.22
0%
17.0%US$3.38US$1.58n/a19
Jun ’24n/a
US$2.27
0%
17.1%US$3.45US$1.61n/a19
May ’24n/a
US$2.33
0%
17.3%US$3.54US$1.66n/a18
Apr ’24n/a
US$2.33
0%
17.7%US$3.57US$1.67n/a16
Mar ’24n/a
US$2.51
0%
19.1%US$3.95US$1.77n/a15
Feb ’24n/a
US$2.59
0%
20.2%US$4.22US$1.81US$1.5015
Jan ’24n/a
US$2.79
0%
38.7%US$6.14US$1.79n/a14
Dec ’23n/a
US$2.71
0%
38.7%US$5.98US$1.75n/a14

Analyst Forecast: Target price is more than 20% higher than the current share price and analysts are within a statistically confident range of agreement.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/20 06:57
End of Day Share Price 2024/12/20 00:00
Earnings2024/06/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Hansoh Pharmaceutical Group Company Limited is covered by 32 analysts. 20 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Sharon ShiBOCI Research Ltd.
Bo LiBofA Global Research
Jin ZhangChina International Capital Corporation Limited